Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/18797

Type
Article
Copyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

DIVERSE INHIBITOR CHEMOTYPES TARGETING TRYPANOSOMA CRUZI CYP51
Gunatilleke, Shamila S. et al. | Date Issued: 2012
Author
Gunatilleke, Shamila S.
Calvet, Claudia M. d'Avila
Johnston, Jonathan B.
Chen, Chiung-Kuang
Erenburg, Grigori
Gut, Jiri
Engel, Juan C.
Ang, Kenny K. H.
Mulvaney, Joseph
Chen, Steven
Arkin, Michelle R.
McKerrow, James H.
Podust, Larissa M.
Affilliation
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Ultraestrutura Celular. Rio de Janeiro, RJ, Brasil.
University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pharmaceutical Chemistry. San Francisco, CA, USA.
University of Western Ontario. King’s University College. London, Ontario, Canada.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA / University of California San Francisco. Department of Medicine. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Small Molecule Discovery Center. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
University of California San Francisco. Sandler Center for Drug Discovery. San Francisco, CA, USA / University of California San Francisco. Department of Pathology. San Francisco, CA, USA.
Abstract
Chagas Disease, a WHO- and NIH-designated neglected tropical disease, is endemic in Latin America and an emerging infection in North America and Europe as a result of population moves. Although a major cause of morbidity and mortality due to heart failure, as well as inflicting a heavy economic burden in affected regions, Chagas Disease elicits scant notice from the pharmaceutical industry because of adverse economic incentives. The discovery and development of new routes to chemotherapy for Chagas Disease is a clear priority.
Keywords in Portuguese
Trypanosoma cruzi
Doença de Chagas
 
Keywords
Trypanosoma cruzi
Chagas Disease
 
Publisher
Public Library of Science
Citation
GUNATILLEKE, Shamila S. et al. Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis, v.6, n.7. e1736, 16p, July 2012.
DOI
10.1371/journal.pntd.0001736
ISSN
1935-2727